Navigation Links
Prescription Chondroitin Sulphate is as Efficacious as Celecoxib and Better Than Placebo in Knee Osteoarthritis
Date:6/13/2016

LONDON, June 13, 2016 /PRNewswire/ --

- A new clinical study, conducted in full compliance with the most recent EMeA (European Medicines Agency) guidelines, shows that prescription chondroitin sulphate reduces pain and improves functional disability significantly better than placebo in patients with knee osteoarthritis (OA) 

- Chondroitin sulphate proves to be equally effective as the anti-inflammatory drug (NSAID) celecoxib

- Patients treated daily, for 6 months, well tolerated chondroitin sulphate 800 mg oral dosage form. No serious treatment-related side effects were reported during the entire period of the study    

IBSA, in occasion of the European Congress of Rheumatology (EULAR 2016), has presented the results of a new multicentre, randomised, double-blind and double-dummy phase III clinical trial named CONCEPT (ChONdroitin vs CElecoxib vs Placebo T rial).

     (Logo: http://photos.prnewswire.com/prnh/20160607/376534LOGO )

The study, designed in full compliance with the most recent EMeA guidelines, was conducted in 16 centers located in Belgium, Czech Republic, Italy, Poland and Switzerland and involved 603 patients with knee OA with the aim to confirm the efficacy and the safety of prescription highly purified chondroitin sulphate versus placebo and celecoxib, as gold reference standard, for a 6-month treatment period.

The results, presented by Prof. Reginster, MD, PhD, Professor of Epidemiology, Public Health and Health Economics (University of Liège, Belgium), during IBSA satellite symposium "What treatment should we adopt as the preferred long-term therapy in knee OA" (http://www.ibsa-international.com/eular2016/) show that the two primary endpoints, the decrease of the Lequesne algo-functional index and the decrease of pain on a VAS scale, resulted both to be statistically significant (p<0.05) vs placebo, confirming the SYSADOA (Sympomatic Slow Acting Drug in OsteoArthritis) effect of chondroitin sulphate. In addition, chondroitin sulphate proves to be equally effective to the active comparator celecoxib and to possess a favourable benefit/risk profile.

"We are very pleased with the outcome of this trial" commented Giuseppe Mautone, Head of IBSA R&D, "since these evidences represent a step forward in the definition of which drugs physicians should adopt for the long term therapy of OA". 

About Osteoarthritis (OA) 

OA currently affects over 40 million Europeans; it accounts for a substantial number of healthcare consultations and is a leading indication for use of prescription drugs. With the increasing aging population, OA is expected to become the fourth leading cause of disability by 2020[1],[2].

The relief of pain, the improvement of the functionality and quality of life are the main goals for the treatment of OA[2]. The main used treatments belong to analgesics and NSAIDs, which are effective but they often cause serious adverse reactions at GI and CV levels.

Several compounds have been investigated and tested so far for their effects on the relief of clinical symptoms and improvement of joint structural changes, but there is still a great debate on which treatment/drug should be adopted as the preferred long-term therapy in knee OA.

About chondroitin sulphate 

IBSA chondroitin sulphate* is a prescription drug with a positive and well consolidated benefit/risk profile. Its efficacy and safety in the treatment of OA has been proved in several clinical trials involving more than 3,900 patients.

The product is currently available in 13 countries in EU and from the date of the first commercialization (1983, Switzerland) more than 55 million of patients have been treated.

*Most common brand names: Condrosulf®, Chondrosulf®.

About IBSA  

IBSA is a medium-size pharmaceutical company headquartered in Lugano, Switzerland.

http://www.ibsa-international.com/home/

Currently the IBSA group employs over 1800 people and is present in over 80 countries through partnerships and local subsidiaries in Italy, France, Hungary, Slovak Republic, Poland, Turkey, China and Scandinavia. The activities cover 8 main treatment areas (pain/inflammation, rheumatology, reproduction and fertility, endocrinology, urology, dermatology and dermocosmetics, respiratory, cardiovascular), with over 60 exclusive patents.

Bibliography 

  1. Conaghan P.G. et al. Ann Rheum Dis. 2014; 73 (8): 1442-5.
  2. Bruyère O. et al. Semin Arthritis Rheum. 2015; 45: S3-S11.

For more information:
Michele Fasola
Medical Marketing Manager
Medical Affairs
IBSA Institut Biochimique SA
Tel: +41-(0)-58-360-10-00
michele.fasola@ibsa.ch
http://www.ibsa-international.com


'/>"/>
SOURCE IBSA
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. In Continued Effort to Fight Opioid Abuse, PA Department of Health Names Meghna Patel to Lead Prescription Drug Monitoring Program
2. In Continued Effort to Fight Opioid Abuse, Pennsylvania Department of Health Names Meghna Patel to Lead Prescription Drug Monitoring Program
3. Some Imported Dietary Supplements and Nonprescription Drug Products May Harm You
4. Tracking the Tracker: The Long Road for Pennsylvanias Prescription Drug Monitoring Program
5. Mallinckrodt CEO Mark Trudeau Urges Support for Missouri Prescription Drug Monitoring Measure to Fight Prescription Drug Abuse
6. CVS Health Reports Dramatic Drop in Prescription Drug Trend to 5 Percent, Despite Rising Drug Prices
7. Pennsylvania Department of Health Joins Other Public Health Agencies in Urging FDA to Issue Warnings for Dangerous Combination of Medications Amid Prescription Drug Overdose Crisis
8. BioElectronics and B. Braun Medical Ltd Apply for Prescription Payment Clearance on the UK Drug Tariff
9. CVS Health To Make Overdose-Reversing Drug Available Without A Prescription At All CVS Pharmacy Locations Across Ohio
10. Pharmacy - Pill Dust - Patient Protection: Madigan Patient Safety - Product Innovation Foundation Announces New Patented Product That Eliminates Dangers Related to Compromised Prescription Medication
11. Indiana Voters Oppose Prescription Requirements for Popular Cold and Allergy Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):